CTOs on the Move

NorthStar Litigation Technologies

www.northstarlit.com

 
NorthStar Litigation Technologies is a Roseland, NJ-based company in the Software and Internet sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Redknee

Established in 1999, Redknee provides critical real-time monetization software to some of the world’s largest communications service providers, delivering the most innovative real-time, pre-integrated billing and customer care solutions in the market. Today, our software addresses the needs of more than 200 service providers and touches one third of the world’s population on a daily basis. Redknee’s focus is on your business. At Redknee, we look beyond to a world where there are no limits to how service providers launch and support new markets, new offerings and new ideas. We believe in driving innovation in global communications and digital services, and are committed to helping all types of service providers from communications, utilities and railways to differentiate themselves with real-time, end-to-end solutions that address the entire subscriber lifecycle. From provisioning, rating, charging, billing, policy management and customer care, Redknee provides the solutions that help drive revenue, increase profitability and advance the customer experience.

CRMIT Solutions

CRMIT Solutions is a leading Salesforce Crest Partner with 4000+ Lightning experience users and 220+ customers across 30+ countries.

Falcon Marketing

Digital Marketing, Online Marketing and Web Development Agency focusing on eCommerce and online marketing. Over 20+ years of combined experience and 80+ team members

Simpler Networks

Simpler Networks is a Dorval, QC-based company in the Software and Internet sector.

Immunome

Immunome is a biotechnology company with a growing pipeline of cancer immunotherapies fueled by the human immune system. Our unique and powerful immunotherapy discovery engine leverages “most highly educated” immune systems from patients who have already learned how to fight off their disease. This proprietary technology platform enables the simultaneous discovery of novel antigens and the patient-derived, native antibodies that target those antigens. We then employ a battery of high-content screening technologies to identify specific and high-affinity antibodies that offer significant therapeutic potential to change the way we treat cancer.